June 2026 Research Update

This month added more information about what treatment may look like over longer periods in real-world care and in longer follow-up from trials: many people had stable nerve-related function measures while transthyretin levels stayed strongly reduced, but progression was not eliminated in all datasets. In other words, the shared picture was more about slowing and stabilizing than reversing the disease, with different studies using different scales and timeframes. [1] [2] [3] [4]

In the HELIOS-A randomized extension, vutrisiran (a gene-silencing medicine) maintained a large average drop in serum transthyretin through 42 months, and several neuropathy and daily-function measures were reported as stable over extended follow-up. About two-thirds of participants had stable walking-disability staging (PND), and adverse events were mostly mild to moderate with no new safety concerns described in this follow-up. [1]

In routine care from a single center in Germany, long-term use of first-generation silencers (patisiran or inotersen) also showed sustained lowering of serum transthyretin, with generally stable neurologic, heart, and nutrition-related measures reported over as long as 6 years. More side effects were reported in the inotersen-treated group, and many patients switched over time to vutrisiran, which the report notes as part of changing practice patterns. [2]

For diflunisal (a transthyretin stabilizer), Swedish registry data showed that several disease scales still worsened gradually over time, including neuropathy and overall staging measures, while heart-failure class stayed about the same. When the registry results were combined with older trial data, the analysis estimated a high probability that diflunisal was better than placebo at 24 months for the Kumamoto score and modified BMI, which supports a slowing effect even though progression continued. [3]

A network meta-analysis pooling randomized trials compared multiple ATTRv-PN medicines indirectly and reported that gene-silencing therapies, especially patisiran and vutrisiran, showed the largest improvements versus placebo in neuropathy scores and quality of life in the available trial data. It did not find clear differences in serious adverse events between active treatments and placebo, but the authors noted uncertainty because trials differed and long-term safety comparisons are hard with limited data. [4]

For patients living with ATTRv with polyneuropathy, these studies mainly add reassurance about what "long-term" treatment can look like in research follow-up and in routine care: sustained lowering of transthyretin and many people remaining stable on key nerve and daily-function measures for years was repeatedly reported. At the same time, the diflunisal registry data make it clear that progression can still happen, even when a medicine appears better than placebo on some measures, so the goal described by these studies is often slowing and stabilization rather than cure. What remains uncertain is how to compare different medicines head-to-head over many years and how individual factors (like variant type and starting disease stage) change long-term results, since several results come from observational data or indirect trial comparisons. [1] [2] [3] [4]

This month, studies looking at nerves and brain involvement focused less on new treatments and more on better ways to measure disease impact and identify higher-risk situations. Two studies in living patients suggested that more sensitive measurements can pick up differences by stage and match how people function day to day, while a transplant-era cohort highlighted a specific pattern of transient neurologic episodes with EEG findings tied to outcomes. [5] [6] [7]

For hand and arm function, the Hand Test System detected differences across ATTRv stages, including changes that were not always captured by a standard timed peg test until later-stage disease. The hand test measures also tracked with disability and quality-of-life questionnaires and with grip or pinch strength, suggesting it reflects real-life function rather than only a lab score, although the authors noted that early carpal tunnel problems could blur interpretation in mild disease. [5]

For blood testing, serum neurofilament light chain (sNfL), a marker linked to nerve fiber damage, was much higher in ATTRV30M patients than in controls and increased with worse walking-disability stage. In this dataset, sNfL did not separate pre-symptomatic carriers from controls, and two other proposed markers (GFAP and PRPH) did not differ across groups, narrowing the list of candidates that look promising for monitoring. [6]

In ATTRV30M patients who previously had liver transplantation, brief transient focal neurologic episodes were reported as common and came in different forms that could resemble seizures, TIA-like events, or migraines. A focal slowing pattern on EEG was linked to having these episodes and was also linked to shorter survival, and cognitive problems tracked with EEG slowing, pointing to EEG as a possible marker of more advanced central nervous system involvement in this specific post-transplant population. [7]

These studies mainly matter as "measurement" research: they describe tools that could make it easier to track how ATTRv affects daily function and to recognize higher-risk neurologic patterns in certain groups. The hand-motor testing and sNfL results support the idea that more sensitive measures may reflect patient experience earlier or more clearly than some traditional tests, but they do not yet show how using these tools changes outcomes. The transplant study is more immediately relevant to people who have had liver transplantation, because it connects specific transient episodes and EEG patterns with prognosis, while still leaving uncertainty about how best to prevent or treat these episodes based on EEG findings alone. [5] [6] [7]

This month added several pieces to the cardiac side of ATTRv: some work tried to separate who is more heart-predominant based on genotype, while other work tested tools to predict rhythm problems or find amyloid using non-heart tissue samples. The overall message was that heart involvement and detection can look very different depending on the person and the test used, so no single shortcut worked across all settings. [8] [9] [10] [11] [12]

In a large Italian database of patisiran-treated ATTRv patients, people with the F64L variant were described as more neurologic-predominant, with milder cardiac findings than non-F64L and also milder than V30M on some cardiac measures (such as interventricular septum thickness and NT-proBNP). Most tracked measures were reported as stable over time in this treated cohort, reinforcing that ATTRv can separate into recognizable patterns by variant even among people receiving the same therapy. [8]

For predicting atrial rhythm problems in cardiac amyloidosis (including ATTRv and AL), a prospective study found that new atrial arrhythmias were common during about 11 months of follow-up. A left atrial ultrasound strain measure called mechanical dispersion (how unevenly the left atrium contracts) predicted who developed new arrhythmias, and it improved prediction beyond left atrial size alone in the model tested. [9]

For tissue-based detection, Congo red staining on subcutaneous fat aspiration had very high specificity and variable sensitivity across amyloid subtypes, with reported sensitivity around 71% for ATTRv in this dataset. A separate paper on biopsy taken during carpal tunnel release highlighted uncertainty in real-world yield: despite prior studies suggesting some positive results, one institutional cohort of 89 African American patients found zero amyloid deposits in 129 specimens, pointing to the need for better ways to choose who benefits from this approach. [10] [11]

A single case report from Japan described hereditary ATTR cardiomyopathy caused by the Ile68Leu variant in a man in his 40s, noting that this variant was absent from East Asian population databases. While one person cannot define what is typical, it expands the list of variants to consider when a Japanese patient has imaging findings consistent with ATTR cardiomyopathy. [12]

For patients and caregivers, these studies help clarify that cardiac ATTRv is not one uniform condition: some variants may more often look nerve-dominant with milder heart signals, and others may be found only when genetic testing is done in the right clinical situation. The atrial-arrhythmia study may matter now in the sense that it identifies an ultrasound measurement that could flag higher short-term risk for rhythm problems in cardiac amyloidosis, but it does not prove that acting on that measurement improves outcomes. The biopsy studies explain why some screening approaches can be useful in some settings (fat aspiration with high specificity) but unreliable in others (carpal tunnel tissue with no deposits in one cohort), leaving open questions about the best testing pathway for different populations. [8] [9] [10] [11] [12]

Two exploratory papers tried to explain ATTR disease at a deeper, more mechanistic level, using either mathematical modeling or lab testing of patient serum. Together they point to possible ways to quantify amyloid formation and to understand effects of treatments beyond the heart muscle itself, but both remain early-stage and are not the same as direct clinical comparisons in patients. [13] [14]

A mechanistic mathematical model of ATTR cardiomyopathy linked transthyretin tetramer breakup and monomer behavior to a single modeled output called monomer efflux, used as a stand-in for disease progression. When fit to lab and phase III trial data, the model estimated larger reductions in this output for acoramidis than for tafamidis or vutrisiran, and it predicted higher monomer efflux in ATTRv than ATTRwt. [13]

Another paper combined lab experiments and patient measurements suggesting blood from ATTR cardiomyopathy patients can cause stress responses in endothelial cells (cells lining blood vessels), and that serum collected after tafamidis treatment reduced these harmful effects in the lab. In a clinical component focused on ATTRwt-CM, arterial stiffness measured by pulse wave velocity improved after tafamidis, and the change tracked with higher serum transthyretin and changes in immune-cell protein recycling activity. [14]

For patients, these studies mainly add understanding rather than something used in routine decision-making today. The modeling work offers a way researchers may compare how different drug types could affect the earliest steps of amyloid formation, but its key output is a surrogate and was not validated as a personal predictor of symptoms or survival. The tafamidis biology study raises the possibility that treatment could influence blood-vessel function and inflammation-related signals, yet the lab findings do not guarantee the same effects in every person, and the clinical observations were limited to ATTRwt in the arterial stiffness analysis. [13] [14]